Clinical Kidney Journal最新文献

{"title":"Intravitreal vascular endothelial growth factor inhibitor systemic and renal toxicity registry.","authors":"Matthew D Nguyen, Ryan Fekrat, Caroline Gee, Arif Nihat Demirci, Sohrab Kharabaf, Dao Le, Mina Tadros, Vu Q Nguyen, Samir Patel, Tai Truong, Rebecca Ahdoot, Ira B Kurtz, Michael Kerr, Abanoub Massoud, Ramy Hanna","doi":"10.1093/ckj/sfaf206","DOIUrl":"https://doi.org/10.1093/ckj/sfaf206","url":null,"abstract":"<p><strong>Background: </strong>Intravitreal vascular endothelial growth factor inhibitors (IVEGFi) are used in the treatment of diabetic retinopathy, age-related macular degeneration (AMD) and central retinal vein obstruction. As we have previously reported, there are an increasing number of cases documenting IVEGFi with renal injury and increased concentrations in the serum. To assess this claim, we have developed a novel reporting system through an electronic registry for cases of suspected VEGFi injury.</p><p><strong>Methods: </strong>A website with multiple data protection sets was created to educate, promote awareness and capture patient cases of suspected IVEGFi toxicity. The website displays the molecular biology of VEGF signaling, the process of absorption into the bloodstream, and study reports showing risks on case, cohort and epidemiologic levels. A Health Insurance Portability and Accountability Act (HIPAA)-compliant patient intake form was designed to collect renal, cardiovascular, cerebrovascular, renal biopsy and function data along with drug type, indication and frequency of administration.</p><p><strong>Results: </strong>In our updated cohort we added 16 total cases from the literature showing signs of renal injury from the patient population receiving VEGFi. In current literature, 46 cases of VEGFi-related renal injury have been documented. To them, we add our 16 cases for a total of 62 cases.</p><p><strong>Conclusion: </strong>The current database for VEGFi-related nephrotoxicity constitutes the largest case series presented for this condition. This study opens the door for future studies to evaluate what subgroups experience acute kidney injury, proteinuria and hypertension exacerbations. Additionally, we may expand on our database to include timeline markers for symptomatic-correlative VEGFi usage and, in time, predictive measures on a larger scale to correlate comorbidity/drug use with drug effect and mechanism of action.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 8","pages":"sfaf206"},"PeriodicalIF":4.6,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal patterns of fluid overload, blood volume and vascular refilling: a prospective study in patients on maintenance hemodialysis.","authors":"Sebastian Mussnig, Simon Krenn, Max Waller, Michael Schmiedecker, Amelie Kurnikowski, Janosch Niknam Saeidi, Luis Naar, Christopher C Mayer, David Keane, Daniel Schneditz, Manfred Hecking, Leszek Pstras","doi":"10.1093/ckj/sfaf199","DOIUrl":"https://doi.org/10.1093/ckj/sfaf199","url":null,"abstract":"<p><strong>Introduction: </strong>Patients on maintenance hemodialysis accumulate excess fluid between treatments. Intradialytic removal of fluid via ultrafiltration is partly compensated by vascular refilling from the interstitial space. Associations between whole-body fluid status and blood volume were previously investigated on the population level. The aim of this observational cohort study was to assess longitudinal changes in fluid compartment volumes on an intra-patient level.</p><p><strong>Methodology: </strong>Pre-dialysis bioimpedance spectroscopy measurements and absolute blood volume estimations were conducted in maintenance hemodialysis patients during 14 consecutive dialysis treatments over 5 weeks. Blood volume was determined using the dialysate bolus method. Longitudinal changes were evaluated using linear mixed models. Correlations were analyzed with repeated measures correlation coefficients ([Formula: see text]).</p><p><strong>Results: </strong>Twenty-five patients were included in the final analysis [88% male, median (quartile 1, quartile 3) age and dialysis vintage of 66.0 years (48.0, 74.0) and 23.5 months (13.5, 34.5), respectively]. Pre-dialysis fluid overload significantly decreased from the first to the third treatment within the week (<i>β</i> = -0.38, <i>P</i> < .01) with no significant within-week changes in euvolemic body mass (<i>β</i>= -0.04, <i>P</i> = .78) or absolute blood volume at treatment start (<i>β</i> = -0.06, <i>P</i> = .65). Fluid overload did not correlate with absolute ([Formula: see text] = 0.10, <i>P</i> = .65) or specific blood volume ([Formula: see text]=0.06, <i>P</i> = .78) at treatment start on an intra-patient level, but correlated moderately with refilling volume ([Formula: see text] = 0.46, <i>P</i> < .01).</p><p><strong>Conclusions: </strong>The observed lack of intra-patient correlations between pre-dialysis fluid overload and blood volume suggests that excess fluid may not necessarily accumulate proportionally in the interstitial and intravascular space, thus challenging previous assumptions regarding within-week changes in fluid compartments.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 8","pages":"sfaf199"},"PeriodicalIF":4.6,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal vein evaluation in venous excess ultrasound (VExUS): is it necessary?","authors":"Masafumi Sakai, Keisuke Yoshida, Kana Shirai, Fumiya Kitano, Yugo Shibagaki, Masahiko Yazawa","doi":"10.1093/ckj/sfaf205","DOIUrl":"10.1093/ckj/sfaf205","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 7","pages":"sfaf205"},"PeriodicalIF":3.9,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12264486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of obinutuzumab in active lupus nephritis.","authors":"Corina-Daniela Ene, Annette Bruchfeld","doi":"10.1093/ckj/sfaf161","DOIUrl":"10.1093/ckj/sfaf161","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 7","pages":"sfaf161"},"PeriodicalIF":3.9,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Recognition of intraglomerular histological features with deep learning in protocol transplant biopsies and their association with kidney function and prognosis.","authors":"","doi":"10.1093/ckj/sfaf178","DOIUrl":"https://doi.org/10.1093/ckj/sfaf178","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/ckj/sfae019.].</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 6","pages":"sfaf178"},"PeriodicalIF":3.9,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144495017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflections on our role as patient representatives for <i>CKJ</i>.","authors":"Takamasa Iwakura, Brooke M Huuskes","doi":"10.1093/ckj/sfaf202","DOIUrl":"https://doi.org/10.1093/ckj/sfaf202","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 7","pages":"sfaf202"},"PeriodicalIF":3.9,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12241847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Major complications of percutaneous native and transplant kidney biopsy: a complete 10-year national prospective cohort study.","authors":"Colin C Geddes, Samira Bell, Kate Buck, Bryan Conway, Vishal Dey, Robert Hunter, Nicola Joss, Michael Kelly, Joe Lakey, Steve Marjoribanks, Wendy Metcalfe, Shona Methven, Lisa Norman, Kate Stevens, Graham Stewart, Jamie Traynor, David Walbaum, Wan Wong, Emily McQuarrie","doi":"10.1093/ckj/sfaf196","DOIUrl":"10.1093/ckj/sfaf196","url":null,"abstract":"<p><strong>Background: </strong>Previous reports of incidence of major complications (MC) of kidney biopsy vary depending on definitions of MC, single or multicentre analysis, and prospective or retrospective data collection. We aimed to provide accurate, unbiased information about the incidence of MC by analysing 10-year data from a prospective national renal biopsy registry.</p><p><strong>Methods: </strong>The Scottish Renal Biopsy Registry has prospectively collected data on all native and transplant kidney biopsies undertaken in the nine adult renal centres in Scotland since 2014. Nephrologists from each centre report demographics, operator, coded indication, coded diagnosis and coded MC.</p><p><strong>Results: </strong>A total of 8476 biopsies were reported in the 10 years between 2014 and 2023 (6167 native, 2309 transplant). The overall incidences of MC following native and transplant kidney biopsy were 2.1% and 1.4%, respectively (<i>P </i>< .001). The most common MC of native kidney biopsy was the requirement for 'arteriography with embolization' (0.63% of biopsies) and the most common MC of transplant biopsy was 'blood transfusion only' (0.30%). Nine deaths (0.15%) and no nephrectomies were attributed to native biopsy, and one death and one nephrectomy were attributed to transplant biopsy. MC were more common in women than men (2.2 vs 1.5%; <i>P </i>= .01). MC incidence was identical for biopsies performed by nephrologists (<i>n</i> = 5373) and radiologists (<i>n</i> = 2709). A positive association between quartile of serum creatinine at the time of native biopsy and incidence of MC diminished when acute kidney injury as indication for biopsy was excluded. Transplant biopsies >10 years after transplant had a higher risk of MC (3.4%).</p><p><strong>Conclusion: </strong>MC of kidney biopsy in the modern era remain rare. This registry analysis provides accurate estimates of risk based on unbiased national data. The increased incidence of MC in women merits further study.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 7","pages":"sfaf196"},"PeriodicalIF":3.9,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety of kappa opioid receptor (KOR) agonists in patients with uraemic pruritus: a systematic review and network meta-analysis.","authors":"Hanqi Yang, Ming Pei, Jingbo Zhai, Zijun Zhou, Yunze Xing, Qiumei Lan, Yixin Zhu, Xuchen Wang, Bo Yang","doi":"10.1093/ckj/sfaf131","DOIUrl":"10.1093/ckj/sfaf131","url":null,"abstract":"<p><strong>Background: </strong>Uraemic pruritus (UP) is an increasingly significant health burden. However, current treatments are often unsatisfactory and associated with numerous adverse reactions. Recently, several large randomized controlled trials (RCTs) have confirmed that kappa opioid receptor (KOR) agonists, which target the endogenous opioid system, are effective in controlling symptoms. We compared the efficacy and safety of currently available KOR agonists for the treatment of UP.</p><p><strong>Methods: </strong>We conducted a systematic review and network meta-analysis (NMA) of RCTs to assess the efficacy and safety of KOR agonists in patients with UP. The primary outcomes were pruritus-related scales and adverse events. Two independent reviewers evaluated RCTs for eligibility and extracted relevant data, with discrepancies resolved by consensus or a third reviewer. We utilized a fixed effects model within a Bayesian framework for the NMA. Dichotomous variables were presented as risk ratios (RRs) and continuous variables were merged using standardized mean differences. Statistical analyses were performed using R 4.2.3 and JAGS 4.3.0. The risk of bias was assessed using the RoB 2 tool and the certainty of findings was rated according to Grading of Recommendations Assessment, Development and Evaluation criteria. The study protocol was registered on PROSPERO (CRD42020169955).</p><p><strong>Results: </strong>Ten studies with 2483 participants were included. Concerning the primary endpoints, difelikefalin at doses of 0.25 µg/kg, 0.5 µg/kg, 1.0 µg/kg and 1.5 µg/kg, nalfurafine at 2.5 µg and 5 µg and nalbuphine at 120 mg were significantly effective in reducing itching severity compared with placebo. For the secondary endpoint, all four doses of difelikefalin were associated with higher rates of adverse events compared with placebo, while other interventions showed rates comparable to those of placebo and did not present statistically significant differences.</p><p><strong>Conclusion: </strong>In summary, difelikefalin at doses of 0.25 µg/kg and 0.5 µg/kg, along with nalfurafine at 0.25 µg/kg and 0.5 µg/kg, can be considered recommended therapeutic options for UP treatment.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 6","pages":"sfaf131"},"PeriodicalIF":3.9,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144495019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Considering the utility of urinary amino acids for early identification of non-diabetic chronic kidney disease.","authors":"Henry H L Wu, David Cantor, Fei Chi, Long The Nguyen, Rajkumar Chinnadurai, Carol A Pollock, Sonia Saad","doi":"10.1093/ckj/sfaf198","DOIUrl":"10.1093/ckj/sfaf198","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 7","pages":"sfaf198"},"PeriodicalIF":3.9,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12264485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The CALCIPHYX trial and its impact on calciphylaxis treatment: what's next?","authors":"Marieta Theodorakopoulou, Björn Meijers","doi":"10.1093/ckj/sfaf193","DOIUrl":"10.1093/ckj/sfaf193","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 7","pages":"sfaf193"},"PeriodicalIF":3.9,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}